Daniel Tan Shao Weng

38PUBLICATIONS
290CO-AUTHORS
Molecular targetsArtificial life and complex adaptive systemsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersSolid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (38)

|Aug 11, 2026
Early EGFR Inhibition Triggers Actionable Tumor and Microenvironmental Remodeling in Lung Cancer.

|Aug 07, 2026
AI-based augmentation of oncology clinical trials.

|Jul 10, 2026
Rethinking Molecular Profiling after First-line Osimertinib.

|May 13, 2026
Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial.

|Mar 26, 2026
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.

Benjamin Besse, Vivek Subbiah, Giuseppe Curigliano

|Jan 15, 2026
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.

Sarah Waliany, Alissa J Cooper, Stephen V Liu

Pageof 7

Frequent Collaborators

8 joint publications

Anders Jacobsen Skanderup

6 joint publications

Aaron C Tan

5 joint publications

Benjamin J Solomon

4 joint publications

Wan-Teck Lim